Scienture Holdings Inc (SCNX)

$0.35 -0.01 (-2.22%)
Market Cap 14.63M
Revenue (ttm) 430,000.00
Net Income (ttm) -41.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9,653.49%
Debt to Equity Ratio 0.00
Volume 273,300
Avg Vol 543,530
Day's Range N/A - N/A
Shares Out 40.63M
Stochastic %K 36%
Beta 3.29
Analysts Strong Sell
Price Target $1.50

Company Profile

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dih...

Industry: Pharmaceutical Retailers
Sector: Healthcare
Phone: 631) 670-6039
Address:
20 Austin Boulevard, Commack, United States
Ottersberger
Ottersberger Jun. 9 at 11:57 AM
$SCNX 800k shares to short on IB…not going easy
0 · Reply
Cpt_Sergio
Cpt_Sergio Jun. 9 at 11:52 AM
$SCNX Shorters won’t give it any chance to move. It’s curse of penny stocks.
0 · Reply
pudge83
pudge83 Jun. 9 at 11:49 AM
$SCNX 👀
0 · Reply
Marketmoverjoe
Marketmoverjoe Jun. 9 at 11:21 AM
$SCNX 20% insider owned. this is bouncing today. any perspective out there
1 · Reply
Ottersberger
Ottersberger Jun. 8 at 6:44 PM
$SCNX bad news around the corner?
1 · Reply
Ottersberger
Ottersberger Jun. 8 at 1:55 PM
$SCNX now it’s awful
0 · Reply
CL80
CL80 Jun. 5 at 11:20 PM
$SCNX awful
0 · Reply
Ottersberger
Ottersberger Jun. 5 at 7:49 PM
$SCNX S&P is down - no worries
1 · Reply
Orian1978
Orian1978 Jun. 5 at 6:43 PM
$SCNX reverse split and additional dilution pretty much guaranteed.
1 · Reply
Thursdays2
Thursdays2 Jun. 5 at 10:45 AM
$SCNX
0 · Reply
Latest News on SCNX
SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC

Jun 4, 2026, 8:00 AM EDT - 5 days ago

SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC

Scienture reveives U.S. patent covering Rezenopy Nasal Spray

2026-06-02T15:04:18.000Z - 6 days ago

Scienture reveives U.S. patent covering Rezenopy Nasal Spray

SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041

Jun 2, 2026, 8:05 AM EDT - 6 days ago

SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041

SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion

May 18, 2026, 8:38 AM EDT - 21 days ago

SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion

Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline

May 7, 2026, 8:05 AM EDT - 4 weeks ago

Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline

Scienture announces third patent granted for Arbli

2026-05-07T03:50:06.000Z - 4 weeks ago

Scienture announces third patent granted for Arbli

SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041

May 6, 2026, 8:05 AM EDT - 4 weeks ago

SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041

Scienture granted 180-day extension to meet Nasdaq minimum bid price

2026-04-15T13:37:53.000Z - 7 weeks ago

Scienture granted 180-day extension to meet Nasdaq minimum bid price

SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update

Mar 30, 2026, 8:07 AM EDT - 2 months ago

SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update

Why Is Scienture Holdings Stock (SCNX) Up Today?

2026-03-11T13:15:15.000Z - 3 months ago

Why Is Scienture Holdings Stock (SCNX) Up Today?

Scienture formalized multiple GPO agreements for Rezenopy

2026-03-11T12:16:19.000Z - 3 months ago

Scienture formalized multiple GPO agreements for Rezenopy

SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions

Mar 11, 2026, 8:05 AM EDT - 3 months ago

SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions

Scienture initiated with a Buy at Maxim

2026-02-24T13:33:22.000Z - 3 months ago

Scienture initiated with a Buy at Maxim

Scienture initiated with a Buy at Maxim

2026-02-24T13:27:59.000Z - 3 months ago

Scienture initiated with a Buy at Maxim

Scienture provides commercial update on Arbli

2026-02-03T13:11:18.000Z - 4 months ago

Scienture provides commercial update on Arbli

SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

Feb 3, 2026, 8:05 AM EST - 4 months ago

SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

Scienture announces USPTO issues patent covering REZENOPY Nasal Spray

2026-01-14T13:10:22.000Z - 5 months ago

Scienture announces USPTO issues patent covering REZENOPY Nasal Spray

SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment

Jan 14, 2026, 8:05 AM EST - 5 months ago

SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment

Scienture provides update on commercial launch of REZENOPY

2025-12-22T13:15:28.000Z - 6 months ago

Scienture provides update on commercial launch of REZENOPY

SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA

Dec 22, 2025, 8:05 AM EST - 6 months ago

SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA

Scienture, BlinkRx announce strategic collaboration to expand access to Arbli

2025-12-10T13:20:49.000Z - 6 months ago

Scienture, BlinkRx announce strategic collaboration to expand access to Arbli

SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

Dec 10, 2025, 8:05 AM EST - 6 months ago

SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025

Dec 2, 2025, 8:05 AM EST - 6 months ago

SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025

Scienture reports Q3 EPS (19c) vs. ($1.34) last year

2025-11-13T13:15:24.000Z - 7 months ago

Scienture reports Q3 EPS (19c) vs. ($1.34) last year

SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update

Nov 13, 2025, 8:05 AM EST - 7 months ago

SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update

Scienture announces addition of Arbli to formularies of national health plans

2025-11-04T13:30:45.000Z - 7 months ago

Scienture announces addition of Arbli to formularies of national health plans

SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans

Nov 4, 2025, 8:05 AM EST - 7 months ago

SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans

Why Did Scienture Stock (SCNX) Soar 45% Today?

2025-10-23T13:06:05.000Z - 8 months ago

Why Did Scienture Stock (SCNX) Soar 45% Today?

Scienture starts commercial sales, fulfillment of first orders of Arbli

2025-10-23T12:26:28.000Z - 8 months ago

Scienture starts commercial sales, fulfillment of first orders of Arbli

SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)

Oct 23, 2025, 8:05 AM EDT - 8 months ago

SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)

Scienture’s Arbli is commercially available through wholesalers nationwide

2025-10-16T13:06:15.000Z - 8 months ago

Scienture’s Arbli is commercially available through wholesalers nationwide

SCIENTURE'S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

Oct 16, 2025, 9:00 AM EDT - 8 months ago

SCIENTURE'S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

Wellgistics Health Announces Executive Management and Board Changes

Oct 13, 2025, 8:00 AM EDT - 8 months ago

Wellgistics Health Announces Executive Management and Board Changes

WGRX

Scienture announces repayment, conversion of outstanding debentures

2025-10-08T13:15:30.000Z - 8 months ago

Scienture announces repayment, conversion of outstanding debentures

Scienture secures multiple commercial GPO agreements for Arbli

2025-10-01T13:06:39.000Z - 8 months ago

Scienture secures multiple commercial GPO agreements for Arbli

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Sep 16, 2025, 8:05 AM EDT - 9 months ago

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

Aug 14, 2025, 9:00 AM EDT - 10 months ago

Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

Aug 13, 2025, 8:05 AM EDT - 10 months ago

SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

Jul 24, 2025, 5:12 PM EDT - 11 months ago

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

Jul 16, 2025, 8:15 AM EDT - 11 months ago

Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

Scienture Holdings Announces Cancelation of ELOC

Jun 17, 2025, 8:05 AM EDT - 1 year ago

Scienture Holdings Announces Cancelation of ELOC

Wellgistics Health Strengthens Executive Team and Board with Strategic Appointments to Accelerate Scale and Drive Shareholder Value

May 28, 2025, 7:45 AM EDT - 1 year ago

Wellgistics Health Strengthens Executive Team and Board with Strategic Appointments to Accelerate Scale and Drive Shareholder Value

WGRX

SCIENTURE Announces Executive Leadership Transition

May 22, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE Announces Executive Leadership Transition

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

May 19, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

Apr 22, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

Apr 8, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

Apr 3, 2025, 8:26 AM EDT - 1 year ago

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

Mar 25, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

Mar 19, 2025, 8:05 AM EDT - 1 year ago

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

Mar 18, 2025, 8:05 AM EDT - 1 year ago

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

Mar 6, 2025, 7:40 AM EST - 1 year ago

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Jan 21, 2025, 8:05 AM EST - 1 year ago

Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

Dec 17, 2024, 8:05 AM EST - 1 year ago

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

Dec 10, 2024, 8:05 AM EST - 1 year ago

Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”

Sep 24, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.

Sep 20, 2024, 11:59 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.

TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team

Aug 5, 2024, 8:01 AM EDT - 2 years ago

TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team

TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million

Jul 26, 2024, 8:01 AM EDT - 2 years ago

TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million

TRxADE Health, Inc. Announces Special Cash Dividend

Jul 9, 2024, 8:05 AM EDT - 2 years ago

TRxADE Health, Inc. Announces Special Cash Dividend

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

May 29, 2024, 4:05 PM EDT - 2 years ago

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Apr 23, 2024, 4:05 PM EDT - 2 years ago

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Scienture Holdings Annual report: Q4 2023

Apr 22, 2024, 8:00 AM EDT - 2 years ago

Scienture Holdings Annual report: Q4 2023

Trxade health, Inc files its 3Q 10Q

Jan 17, 2024, 9:07 AM EST - 2 years ago

Trxade health, Inc files its 3Q 10Q

Scienture Holdings Quarterly report: Q3 2023

Jan 16, 2024, 7:00 AM EST - 2 years ago

Scienture Holdings Quarterly report: Q3 2023

Scienture Holdings Earnings release: Q3 2023

Jan 16, 2024, 7:00 AM EST - 2 years ago

Scienture Holdings Earnings release: Q3 2023

TRxADE Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q.

Nov 29, 2023, 6:13 PM EST - 2 years ago

TRxADE Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q.

TrxADE Health, Inc. affirms its commitment to the pharmaceutical space via its subsidiary Trxade, Inc. which operates the pharmaceutical marketplace and added more members in the third quarter of 2023.

Oct 17, 2023, 8:05 AM EDT - 2 years ago

TrxADE Health, Inc. affirms its commitment to the pharmaceutical space via its subsidiary Trxade, Inc. which operates the pharmaceutical marketplace and added more members in the third quarter of 2023.

Superlatus Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail Sales

Oct 12, 2023, 8:05 AM EDT - 2 years ago

Superlatus Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail Sales

Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

Oct 4, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, Is Gearing Up To Make Big Splashes In the $151 Billion Snacks Industry with its Acquisition of The Urgent Company Inc.

Sep 7, 2023, 9:00 AM EDT - 2 years ago

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, Is Gearing Up To Make Big Splashes In the $151 Billion Snacks Industry with its Acquisition of The Urgent Company Inc.

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, To Acquire The Urgent Company to Expand its Reach In The Sustainable Foods Market

Sep 6, 2023, 9:45 AM EDT - 2 years ago

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, To Acquire The Urgent Company to Expand its Reach In The Sustainable Foods Market

Ottersberger
Ottersberger Jun. 9 at 11:57 AM
$SCNX 800k shares to short on IB…not going easy
0 · Reply
Cpt_Sergio
Cpt_Sergio Jun. 9 at 11:52 AM
$SCNX Shorters won’t give it any chance to move. It’s curse of penny stocks.
0 · Reply
pudge83
pudge83 Jun. 9 at 11:49 AM
$SCNX 👀
0 · Reply
Marketmoverjoe
Marketmoverjoe Jun. 9 at 11:21 AM
$SCNX 20% insider owned. this is bouncing today. any perspective out there
1 · Reply
Ottersberger
Ottersberger Jun. 8 at 6:44 PM
$SCNX bad news around the corner?
1 · Reply
Ottersberger
Ottersberger Jun. 8 at 1:55 PM
$SCNX now it’s awful
0 · Reply
CL80
CL80 Jun. 5 at 11:20 PM
$SCNX awful
0 · Reply
Ottersberger
Ottersberger Jun. 5 at 7:49 PM
$SCNX S&P is down - no worries
1 · Reply
Orian1978
Orian1978 Jun. 5 at 6:43 PM
$SCNX reverse split and additional dilution pretty much guaranteed.
1 · Reply
Thursdays2
Thursdays2 Jun. 5 at 10:45 AM
$SCNX
0 · Reply
BinaryLogic
BinaryLogic Jun. 4 at 8:18 PM
$SCNX The Company is scheduled for 6/09 presentation at Small Cap Showcase (below), which can serve as a good platform to discuss Arbli progress and Rezenopy launch, respectively. The SP is consolidating in the interim at/around $0.4 - the prior support is now resistance until meaningful progress is made on launch/execution. https://www.stocktitan.net/news/SCNX/scienture-to-present-at-the-small-cap-showcase-wtr-insights-on-june-d7ezizev7tm9.html
0 · Reply
Ottersberger
Ottersberger Jun. 3 at 1:50 PM
$SCNX
0 · Reply
Diverstj981
Diverstj981 Jun. 2 at 2:35 PM
$SCNX And to think these uncommunicative clowns asked shareholders to approve 1.5B share dilution back in December. Maybe if you idiots spoke the F up once in a while investors would feel differently about your "leadership".
0 · Reply
djp70
djp70 Jun. 2 at 12:33 PM
$SCNX Rezenopy launch is now mid July. Perr Global newswire article.
3 · Reply
khaliddaman
khaliddaman Jun. 1 at 4:42 PM
$SCNX we don't care fkoff cfo 🤑🤑🤫🤫🤮🤮
0 · Reply
Ottersberger
Ottersberger Jun. 1 at 1:53 PM
$SCNX 50k wall @ .40 🤮
0 · Reply
djp70
djp70 Jun. 1 at 1:23 PM
$SCNX CFO resigned.
1 · Reply
BinaryLogic
BinaryLogic May. 30 at 9:17 PM
$SCNX Rezenopy targets the domestic (US) naloxone market, which is roughly $0.5-1.0B, expected to rise to $1.3-2.4B over the coming decade. Rezenopy will be the highest strength option in this market and the Company already has commercial/distribution channels established from Arbli. Every 1% market penetration equates to $5.0M, and SCNX excellent GM 80-90% should translate these sales to the bottom line. The Company is expecting to be profitable by 2027 - Rezenopy is scheduled to launch this quarter (Q2). Again-execution (Arbli + Rezenopy) leads to multiplier upside (IMO), but the Company will have to deliver on sales.
1 · Reply
Ottersberger
Ottersberger May. 30 at 5:31 PM
$SCNX do we c news on monday? Launch day of REZENOBY 😍
1 · Reply
BillionaireMotion
BillionaireMotion May. 29 at 6:02 PM
$SCNX bioo one
0 · Reply
BinaryLogic
BinaryLogic May. 29 at 8:43 AM
$SCNX [Again]
0 · Reply
Ottersberger
Ottersberger May. 28 at 7:50 PM
$SCNX think it’s starting for news on monday
0 · Reply